The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
Massimiliano BonifacioMario TiribelliMaria Cristina MiggianoElisabetta AbruzzeseGianni BinottoLuigi ScaffidiMaddalena CordioliDaniela DamianiEros Di BonaMalgorzata Monika TrawinskaIlaria TanasiMaria Vittoria DubbiniVanessa VelottaGiulia CeccarelliElisabetta PierdomenicoMariella Lo SchiricoGianpietro SemenzatoMarco RuggeriRenato FaninEvelina TacconelliGiovanni PizzoloMauro KramperaPublished in: Cancer medicine (2021)
Our data confirm that the course of SARS-CoV-2 infection in patients with CML is generally mild and reassure about the safety of continuing TKIs during the COVID-19 pandemic. Furthermore, we suggest that patients with CML succeed to mount an antibody response after exposure to SARS-CoV-2, similar to the general population.